Search

Your search keyword '"Aljurf, M"' showing total 778 results
Start Over Author "Aljurf, M"

Refine your results

more »

more »

more »

more »

more »
778 results on '"Aljurf, M"'

102. PF775 MONOSOMY 7 ALONE OR WITH OTHER CHROMOSOMAL ABNORMALITIES SIGNIFICANTLY AFFECT SURVIVAL OF SECONDARY AML PATIENTS TREATED WITH ALLOGENEIC- SCT

Author

Hassanein, M., primary, Aljurf, M., additional, Ahmed, S., additional, Hanbali, A., additional, Almohareb, F., additional, Alsharif, F., additional, Alahmari, A., additional, Alzahrani, H., additional, Shaheen, M., additional, Alhayli, S., additional, Chaudhri, N., additional, Rashed, W., additional, Alfraih, F., additional, Elfakih, R., additional, and Sharhrukh, H., additional

Published
2019
Full Text
View/download PDF

103. Erratum: Impact of HLA mismatch direction on outcomes after umbilical cord blood transplantation for hematological malignant disorders: a retrospective Eurocord-EBMT analysis

Author

Cunha, R, Loiseau, P, Ruggeri, A, Sanz, G, Michel, G, Iori, A P, Socié, G, Arcese, W, Picardi, A, Dias de Heredia, C, Rio, B, Locatelli, F, O'Brien, T A, Yakoub-Agha, I, Diaz, M A, Milpied, N, Bittencourt, H, Souza, M P, Aljurf, M, Charron, D, Boudjedir, K, Labopin, M, Gluckman, E, and Rocha, V

Published
2014
Full Text
View/download PDF

105. Allogeneic stem cell transplantation in second complete remission for core binding factor acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Author

Halaburda, K., Labopin, M. (Myriam), Mailhol, A., Socie, G. (Gerard), Craddock, C.F. (Charles), Aljurf, M, Beelen, D, Cornelissen, J.J. (Jan), Bourhis, J. H., Labussiere-Wallet, H., Blaise, D. (Didier), Gedde-Dahl, T., Gilleece, M., Yakoub-Agha, I. (I.), Mufti, G.J. (Ghulam), Esteve, J. (Jordi), Mohty, M. (Mohamad), Nagler, A. (Arnon), Halaburda, K., Labopin, M. (Myriam), Mailhol, A., Socie, G. (Gerard), Craddock, C.F. (Charles), Aljurf, M, Beelen, D, Cornelissen, J.J. (Jan), Bourhis, J. H., Labussiere-Wallet, H., Blaise, D. (Didier), Gedde-Dahl, T., Gilleece, M., Yakoub-Agha, I. (I.), Mufti, G.J. (Ghulam), Esteve, J. (Jordi), Mohty, M. (Mohamad), and Nagler, A. (Arnon)

Abstract

Core binding factor acute myeloid leukemia (AML) comprises two subtypes with distinct cytogenetic abnormalities of either t(8;21)(q22;q22) or inv(16)(p13q22)/t(16;16)(p13;q22). Since longterm response to chemotherapy in these leukemias is relatively good, allogeneic hematopoietic stem cell transplantation is considered in patients who relapse and achieve second complete remission. To evaluate the outcomes of allogeneic transplantation in this indication, we studied 631 patients reported to the European Society for Blood and Marrow Transplantation Registry between the years 2000 and 2014. Leukemia-free survival probabilities at two and five years were 59.1% and 54.1%, while overall survival probabilities were 65% and 58.2%, respectively. The incidence of relapse and risk of non-relapse mortality at the same time points were 19.8% and 22.5% for relapse and 20.9% and 23.3% for non-relapse mortality, respectively. The most important adverse factors influencing leukemia-free and overall survival were: leukemia with t(8;21), presence of three or more additional chromosomal abnormalities, and Karnofsky performance score <80. Relapse risk was increased in t(8;21) leukemia and associated with additional cytogenetic abnormalities as well as reduced intensity conditioning. Measurable residual disease in molecular evaluation before transplantation was associated with increased risk of relapse and inferior leukemia-free survival.

Published
2018
Full Text
View/download PDF

106. Quantitative and qualitative differences in use and trends of hematopoietic stem cell transplantation: a Global Observational Study

Author

Gratwohl A, Baldomero H, Gratwohl M, Aljurf M, Bouzas LF, Horowitz MM, Kodera Y, Lipton J, Iida M, Pasquini MC, Passweg JR, Szer J, Madrigal A, Frauendorfer K, and Niederwieser D

Abstract

Fifty five years after publication of the first hematopoietic stem cell transplantation this technique has become an accepted treatment option for defined hematologic and non hematologic disorders. There is considerable interest in understanding differences in its use and trends on a global level and the macro economic factors associated with these differences. Data on the numbers of hematopoietic stem cell transplants performed in the 3 year period 2006 2008 were obtained from Worldwide Network for Blood and Marrow Transplantation member registries and from transplant centers in countries without registries. Population and macro economic data were collected from the World Bank and from the International Monetary Fund. Transplant rates were analyzed by indication donor type country and World Health Organization regional offices areas and related to selected health care indicators using single and multiple linear regression analyses. Data from a total of 146808 patients were reported by 1411 teams from 72 countries over five continents. The annual number of transplants increased worldwide with the highest relative increase in the Asia Pacific region. Transplant rates increased preferentially in high income countries (P=0.02) not in low or medium income countries. Allogeneic transplants increased for myelodysplasia chronic lymphocytic leukemia acute leukemias and non malignant diseases but decreased for chronic myelogenous leukemia. Autologous transplants increased for autoimmune and lymphoproliferative diseases but decreased for leukemias and solid tumors. Transplant rates (P

Published
2013

107. Pre-existing invasive fungal infection is not a contraindication for allogeneic HSCT for patients with hematologic malignancies : A CIBMTR study

Author

Maziarz, R. T., Brazauskas, R., Chen, M., McLeod, A., Martino, R., Wingard, John R, Aljurf, M. D., Battiwalla, M., Dvorak, Christopher C., Geroge, B., Guinan, E.C., Hale, G.A., Lazarus, Hillard M, Lee, Wen-Jane, Liesveld, J. L., Ramanathan, Muthalagu, Reddy, V., Savani, Bipin N, Smith, F. O., Strasfeld, L., Taplitz, R. A., Ustun, Celalettin, Boeckh, M. J., Gea-Banacloche, J., Lindemans, C. A., Auletta, Jeffery J, Riches, Marcie L, Maziarz, R. T., Brazauskas, R., Chen, M., McLeod, A., Martino, R., Wingard, John R, Aljurf, M. D., Battiwalla, M., Dvorak, Christopher C., Geroge, B., Guinan, E.C., Hale, G.A., Lazarus, Hillard M, Lee, Wen-Jane, Liesveld, J. L., Ramanathan, Muthalagu, Reddy, V., Savani, Bipin N, Smith, F. O., Strasfeld, L., Taplitz, R. A., Ustun, Celalettin, Boeckh, M. J., Gea-Banacloche, J., Lindemans, C. A., Auletta, Jeffery J, and Riches, Marcie L

Published
2017

108. Impact of pre-transplant depression on outcomes of allogeneic and autologous hematopoietic stem cell transplantation

Author

El-Jawahri, A, Chen, Y-B, Brazauskas, R, He, N, Lee, SJ, Knight, JM, Majhail, N, Buchbinder, D, Schears, RM, Wirk, BM, Wood, WA, Ahmed, I, Aljurf, M, Szer, J, Beattie, SM, Battiwalla, M, Dandoy, C, Diaz, M-A, D'Souza, A, Freytes, CO, Gajewski, J, Gergis, U, Hashmi, SK, Jakubowski, A, Kamble, RT, Kindwall-Keller, T, Lazarus, HM, Malone, AK, Marks, DI, Meehan, K, Savani, BN, Olsson, RF, Rizzieri, D, Steinberg, A, Speckhart, D, Szwajcer, D, Schoemans, H, Seo, S, Ustun, C, Atsuta, Y, Dalal, J, Sales-Bonfim, C, Khera, N, Hahn, T, Saber, W, El-Jawahri, A, Chen, Y-B, Brazauskas, R, He, N, Lee, SJ, Knight, JM, Majhail, N, Buchbinder, D, Schears, RM, Wirk, BM, Wood, WA, Ahmed, I, Aljurf, M, Szer, J, Beattie, SM, Battiwalla, M, Dandoy, C, Diaz, M-A, D'Souza, A, Freytes, CO, Gajewski, J, Gergis, U, Hashmi, SK, Jakubowski, A, Kamble, RT, Kindwall-Keller, T, Lazarus, HM, Malone, AK, Marks, DI, Meehan, K, Savani, BN, Olsson, RF, Rizzieri, D, Steinberg, A, Speckhart, D, Szwajcer, D, Schoemans, H, Seo, S, Ustun, C, Atsuta, Y, Dalal, J, Sales-Bonfim, C, Khera, N, Hahn, T, and Saber, W

Published
2017

109. Pre-existing invasive fungal infection is not a contraindication for allogeneic HSCT for patients with hematologic malignancies: A CIBMTR study

Author

UMC Utrecht, SCT patientenzorg, Child Health, Maziarz, R. T., Brazauskas, R., Chen, M., McLeod, A., Martino, R., Wingard, John R, Aljurf, M. D., Battiwalla, M., Dvorak, Christopher C., Geroge, B., Guinan, E.C., Hale, G.A., Lazarus, Hillard M, Lee, Wen-Jane, Liesveld, J. L., Ramanathan, Muthalagu, Reddy, V., Savani, Bipin N, Smith, F. O., Strasfeld, L., Taplitz, R. A., Ustun, Celalettin, Boeckh, M. J., Gea-Banacloche, J., Lindemans, C. A., Auletta, Jeffery J, Riches, Marcie L, UMC Utrecht, SCT patientenzorg, Child Health, Maziarz, R. T., Brazauskas, R., Chen, M., McLeod, A., Martino, R., Wingard, John R, Aljurf, M. D., Battiwalla, M., Dvorak, Christopher C., Geroge, B., Guinan, E.C., Hale, G.A., Lazarus, Hillard M, Lee, Wen-Jane, Liesveld, J. L., Ramanathan, Muthalagu, Reddy, V., Savani, Bipin N, Smith, F. O., Strasfeld, L., Taplitz, R. A., Ustun, Celalettin, Boeckh, M. J., Gea-Banacloche, J., Lindemans, C. A., Auletta, Jeffery J, and Riches, Marcie L

Published
2017

110. Thiotepa-based conditioning for allogeneic stem cell transplantation in acute lymphoblastic leukemia-A survey from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Author

Eder, S, Beohou, E, Labopin, M, Sanz, J, Finke, J, Arcese, W, Or, R, Bonifazi, F, Aljurf, M, Socie, G, Passweg, J, Giebel, S, Mohty, M, and Nagler, A

Subjects
Adult, Male, Transplantation Conditioning, Adolescent, Hematopoietic Stem Cell Transplantation, Graft vs Host Disease, Middle Aged, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Disease-Free Survival, Young Adult, Histocompatibility, Humans, Transplantation, Homologous, Female, Settore MED/15 - Malattie del Sangue, Antineoplastic Agents, Alkylating, Thiotepa, Aged, Retrospective Studies
Abstract

In this study, we analyzed a thiotepa-based conditioning regimen for allogeneic stem cell transplantation in adults with acute lymphoblastic leukemia, using the EBMT database. A total of 323 patients were identified. The median age was 43 years. Disease status at transplant was first complete remission (CR1) in 48.9%, CR2 in 21.7%, CR3 in 6.2%, while 23.2% of the patients had an active disease at the time of transplant. This was performed from a HLA-matched sibling (49.8%) or a matched-unrelated donor (51.2%). The incidence of acute graft-vs.-host disease (GvHD) (grade II) was 26.6%, while chronic GvHD occurred in 35.9% of the patients at 1 year (24.6% with extensive disease). With a median follow-up of 16.8 months, the nonrelapse mortality was 12.4 and 25.3% at 100 days and 1 year, respectively. The relapse incidence at 1 year was 33.3% with no difference for patients in CR1 (27%). The one-year leukemia-free survival (LFS) and overall survival (OS) were 57 and 66%, respectively for the entire cohort and 50 and 66%, respectively in patients in CR1. Thiotepa/busulfan ± melphalan (n = 213) in comparison to thiotepa/other (n = 110) conditioning regimen resulted in higher relapse incidence at 1 year (34.9 vs. 30.3%, P = 0.016) and lower LFS (38.8 vs. 45.9%, P = 0.0203), while nonrelapse mortality (23.8 vs. 26.3%, n.s.) and OS (59.6 vs. 51.1%, P = 0.109) did not differ. This large study suggests that a thiotepa-based conditioning for allogeneic transplantation in acute lymphoblastic leukemia is feasible and effective, with the main outcomes being comparable to those achieved with other regimens. Am. J. Hematol. 92:18-22, 2017. © 2016 Wiley Periodicals, Inc.

Published
2016

111. ECIL guidelines for treatment of Pneumocystis jirovecii pneumonia in non-HIV-infected haematology patients

Author

Maschmeyer, G., Helweg-Larsen, J., Pagano, L., Robin, C., Cordonnier, C., Akova M, Schellongowski P., Aljurf, M, Averbuch, D, Barnes, R, Blennow, O, Bochud, Py, Bouza, E, Bretagne, S, Brüggemann, R, Calandra, T, Carratalà, J, Cesaro, S, Cordonnier, C, Cornely, O, Dalianis, T, de la Camara, R, Donnelly, P, Drgona, L, Duarte, R, Einsele, H, Engelhard, D, Fox, C, Girmenia, C, Groll, A, Heldal, D, Helweg-Larsen, J, Herbrecht, R, Hirsch, H, Johnson, E, Klyasova, G, Koskuenvo, M, Lagrou, K, Lewis, Re, Ljungman, P, Maertens, J, Maschmeyer, G, Mikulska, M, Nucci, M, Padoin, C, Pagano, L, Pagliuca, A, Racil, Z, Ribaud, P, Rinaldo, C, Rizzi-Puechal, V, Roilides, E, Robin, C, Rovira, M, Rupp, M, Sanchez, S, Schellongowski, P, Sedlacek, P, Sinko, J, Slavin, M, Ferreira, Is, Styczynski, J, Tissot, F, Viscoli, C, Ward, K, and Witschi, At.

Subjects
0301 basic medicine, Microbiology (medical), medicine.medical_specialty, Primaquine, Antifungal Agents, medicine.medical_treatment, 030106 microbiology, Pneumocystis carinii, Trimethoprim, 03 medical and health sciences, Internal medicine, Trimethoprim, Sulfamethoxazole Drug Combination, medicine, Humans, Pharmacology (medical), immunocompromised host, Pharmacology, Mechanical ventilation, Sulfamethoxazole Drug Combination, medicine.diagnostic_test, Pneumocystis, business.industry, Clindamycin, Pneumonia, Pneumocystis, Pneumonia, medicine.disease, Pnoumocistis jirovecii therapy, Surgery, Settore MED/15 - MALATTIE DEL SANGUE, Regimen, lnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4], Infectious Diseases, Bronchoalveolar lavage, Administration, Intravenous, Hematologic Neoplasms, Respiratory failure, Administration, Intravenous, business, Inflammatory diseases Radboud Institute for Molecular Life Sciences [Radboudumc 5], immunocompromised host, Pnoumocistis jirovecii therapy, medicine.drug
Abstract

The initiation of systemic antimicrobial treatment of Pneumocystis jirovecii pneumonia (PCP) is triggered by clinical signs and symptoms, typical radiological and occasionally laboratory findings in patients at risk of this infection. Diagnostic proof by bronchoalveolar lavage should not delay the start of treatment. Most patients with haematological malignancies present with a severe PCP; therefore, antimicrobial therapy should be started intravenously. High-dose trimethoprim/sulfamethoxazole is the treatment of choice. In patients with documented intolerance to this regimen, the preferred alternative is the combination of primaquine plus clindamycin. Treatment success should be first evaluated after 1 week, and in case of clinical non-response, pulmonary CT scan and bronchoalveolar lavage should be repeated to look for secondary or co-infections. Treatment duration typically is 3 weeks and secondary anti-PCP prophylaxis is indicated in all patients thereafter. In patients with critical respiratory failure, non-invasive ventilation is not significantly superior to intubation and mechanical ventilation. The administration of glucocorticoids must be decided on a case-by-case basis.

Published
2016

112. HCT outcome in adult patients with Fanconi anemia

Author

Ehninger, G., Dufour, C., Risitano, A., Michallet, M., Kroger, N., Boulad, F., Bierings, M., Bonfim, C., Knol, C., Zecca, M., Esquirol, A., Sucak, G., Othman, T. B., Socie, G., Porcher, R., Aljurf, M., Mehta, P., de la Tour, R. Peffault, McQuaker, G., and Thomson, K.

Published
2016

117. Stem cell transplantation in severe congenital neutropenia: An analysis from the European Society for Blood and Marrow Transplantation

Author

Fioredda, F., Iacobelli, S., Biezen, A. van, Gaspar, B., Ancliff, P., Donadieu, J., Aljurf, M., Peters, C., Calvillo, M., Matthes-Martin, S., Morreale, G., van't Veer-Tazelaar, N., Wreede, L. de, Seraihy, A. al, Yesilipek, A., Fischer, A., Bierings, M., Ozturk, G., Smith, O., Veys, P., Ljungman, P., Latour, R.P. de, Codina, J.S.D., Or, R., Ganser, A., Afanasyev, B., Wynn, R., Kalwak, K., Marsh, J., Dufour, C., Pediat Dis Working Parties Europea, Fioredda, Francesca, Iacobelli, Simona, Van Biezen, Anja, Gaspar, Bobby, and Risitano, ANTONIO MARIA

Subjects
Male, Graft Rejection, medicine.medical_treatment, Graft vs Host Disease, Hematopoietic stem cell transplantation, Biochemistry, Allograft, Retrospective Studie, Cumulative incidence, Non-U.S. Gov't, Child, Societies, Medical, Incidence (epidemiology), Research Support, Non-U.S. Gov't, Histocompatibility Testing, Incidence, Medicine (all), Hematopoietic Stem Cell Transplantation, Hematology, Allografts, Clinical Trial, Multicenter Study, Europe, surgical procedures, operative, Child, Preschool, Acute Disease, Cyclosporine, Female, Unrelated Donors, Kostmann syndrome, Human, Adult, medicine.medical_specialty, Neutropenia, Adolescent, Immunology, Research Support, Settore MED/01 - Statistica Medica, Middle East, Internal medicine, Medical, medicine, Journal Article, Humans, Aplastic anemia, Congenital Neutropenia, Preschool, Retrospective Studies, business.industry, Unrelated Donor, Cell Biology, medicine.disease, Surgery, Transplantation, Methotrexate, business, Societies
Abstract

Allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative treatment of severe congenital neutropenia (SCN), but data on outcome are scarce. We report on the outcome of 136 SCN patients who underwent HSCT between 1990 and 2012 in European and Middle East centers. The 3-year overall survival (OS) was 82%, and transplant-related mortality (TRM) was 17%. In multivariate analysis, transplants performed under the age of 10 years, in recent years, and from HLA-matched related or unrelated donors were associated with a significantly better OS. Frequency of graft failure was 10%. Cumulative incidence (day +90) of acute graft-versus-host disease (GVHD) grade 2-4 was 21%. In multivariate analysis, HLA-matched related donor and prophylaxis with cyclosporine A and methotrexate were associated with lower occurrence of acute GVHD. Cumulative incidence (1 year) of chronic GVHD was 20%. No secondary malignancies occurred after a median follow-up of 4.6 years. These data show that the outcome of HSCT for SCN from HLA-matched donors, performed in recent years, in patients younger than 10 years is acceptable. Nevertheless, given the TRM, a careful selection of HSCT candidates should be undertaken.

Published
2015

118. Evaluation of eltrombopag in thrombocytopenia post Hematopoietic cell transplantation

Author

Samarkandi, H., Al Nahedh, M., Alfattani, A., Alsharif, F., Bakshi, N., Rasheed, W., Alfraih, F., Alhumaid, M., Alkhudair, Nora, Alhayli, S., Alsaedi, H., Shaheen, M., Hanbali, A., Hashmi, S.K., Devol, E., Alseraihy, A., Alzahrani, H., and Aljurf, M.

Abstract

Thrombocytopenia remains a life-threatening late complication of HCT with an incidence of 5–20%. Currently, there is no approved drug for the treatment of persistent thrombocytopenia post HCT and platelet transfusion is the maintain stay of treatment. Eltrombopag is approved for the treatment of thrombocytopenia associated with different diseases, however; data on eltrombopag treatment post HSCT are limited.

Published
2024
Full Text
View/download PDF

119. Prospective study of rabbit antithymocyte globulin and ciclosporin for aplastic anemia from the EBMT Severe Aplastic Anemia Working Party

Author

Marsh JC, Bacigalupo A, Schrezenmeier H, Tichelli A, Passweg JR, Killick SB, Warren AJ, Foukaneli T, Aljurf M, Al Zahrani HA, Schafhausen P, Roth A, Franzke A, Brummendorf TH, Dufour C, Oneto R, Sedgwick P, Barrois A, Kordasti S, Elebute MO, Mufti GJ, Socie G., RISITANO, ANTONIO MARIA, Marsh, Jc, Bacigalupo, A, Schrezenmeier, H, Tichelli, A, Risitano, ANTONIO MARIA, Passweg, Jr, Killick, Sb, Warren, Aj, Foukaneli, T, Aljurf, M, Al Zahrani, Ha, Schafhausen, P, Roth, A, Franzke, A, Brummendorf, Th, Dufour, C, Oneto, R, Sedgwick, P, Barrois, A, Kordasti, S, Elebute, Mo, Mufti, Gj, and Socie, G.

Published
2012

120. Bone marrow versus peripheral blood sibling transplants in acquired aplastic anemia: survival advantage for marrow in all age groups

Author

Bacigalupo A, Socie' G, Schrezenmeier H, Tichelli A, Locasciulli A, Fuhrer M, Dufour C, Passweg J, Oneto R, Aljurf M, Flynn C, Mialou V, Hamladji RM, Marsh J., RISITANO, ANTONIO MARIA, Bacigalupo, A, Socie', G, Schrezenmeier, H, Tichelli, A, Locasciulli, A, Fuhrer, M, Risitano, ANTONIO MARIA, Dufour, C, Passweg, J, Oneto, R, Aljurf, M, Flynn, C, Mialou, V, Hamladji, Rm, and Marsh, J.

Published
2012

121. The incidence, mortality and timing of Pneumocystis jiroveci pneumonia after hematopoietic cell transplantation : A CIBMTR analysis

Author

Williams, K. M., Ahn, K. W., Chen, M., Aljurf, M. D., Agwu, A. L., Chen, A. R., Walsh, T. J., Szabolcs, P., Boeckh, M. J., Auletta, J. J., Lindemans, C. A., Zanis-Neto, J., Malvezzi, M., Lister, J., De Toledo Codina, J. S., Sackey, K., Chakrabarty, J. L H, Ljungman, P., Wingard, J. R., Seftel, M. D., Seo, S., Hale, G. A., Wirk, B., Smith, M S, Savani, B. N., Lazarus, H. M., Marks, D. I., Ustun, C., Abdel-Azim, H., Dvorak, C. C., Szer, J., Storek, J., Yong, A., Riches, M. R., Williams, K. M., Ahn, K. W., Chen, M., Aljurf, M. D., Agwu, A. L., Chen, A. R., Walsh, T. J., Szabolcs, P., Boeckh, M. J., Auletta, J. J., Lindemans, C. A., Zanis-Neto, J., Malvezzi, M., Lister, J., De Toledo Codina, J. S., Sackey, K., Chakrabarty, J. L H, Ljungman, P., Wingard, J. R., Seftel, M. D., Seo, S., Hale, G. A., Wirk, B., Smith, M S, Savani, B. N., Lazarus, H. M., Marks, D. I., Ustun, C., Abdel-Azim, H., Dvorak, C. C., Szer, J., Storek, J., Yong, A., and Riches, M. R.

Published
2016

122. Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients

Author

University of Helsinki, Department of Medicine, Mohty, M., Malard, F., Abecassis, M., Aerts, E., Alaskar, A. S., Aljurf, M., Arat, M., Bader, P., Baron, F., Bazarbachi, A., Blaise, D., Ciceri, F., Corbacioglu, S., Dalle, J-H, Dignan, F., Fukuda, T., Huynh, A., Masszi, T., Michallet, M., Nagler, A., NiChonghaile, M., Okamoto, S., Pagliuca, A., Peters, C., Petersen, F. B., Richardson, P. G., Ruutu, T., Savani, B. N., Wallhult, E., Yakoub-Agha, I., Duarte, R. F., Carreras, E., University of Helsinki, Department of Medicine, Mohty, M., Malard, F., Abecassis, M., Aerts, E., Alaskar, A. S., Aljurf, M., Arat, M., Bader, P., Baron, F., Bazarbachi, A., Blaise, D., Ciceri, F., Corbacioglu, S., Dalle, J-H, Dignan, F., Fukuda, T., Huynh, A., Masszi, T., Michallet, M., Nagler, A., NiChonghaile, M., Okamoto, S., Pagliuca, A., Peters, C., Petersen, F. B., Richardson, P. G., Ruutu, T., Savani, B. N., Wallhult, E., Yakoub-Agha, I., Duarte, R. F., and Carreras, E.

Abstract

Sinusoidal obstruction syndrome, also known as veno-occlusive disease (SOS/VOD), is a potentially life threatening complication that can develop after hematopoietic cell transplantation. Although SOS/VOD progressively resolves within a few weeks in most patients, the most severe forms result in multi-organ dysfunction and are associated with a high mortality rate (480%). Therefore, careful attention must be paid to allow an early detection of SOS/VOD, particularly as drugs have now proven to be effective and licensed for its treatment. Unfortunately, current criteria lack sensitivity and specificity, making early identification and severity assessment of SOS/VOD difficult. The aim of this work is to propose a new definition for diagnosis, and a severity-grading system for SOS/VOD in adult patients, on behalf of the European Society for Blood and Marrow Transplantation.

Published
2016

123. The incidence, mortality and timing of Pneumocystis jiroveci pneumonia after hematopoietic cell transplantation: A CIBMTR analysis

Author

UMC Utrecht, SCT patientenzorg, Child Health, Williams, K. M., Ahn, K. W., Chen, M., Aljurf, M. D., Agwu, A. L., Chen, A. R., Walsh, T. J., Szabolcs, P., Boeckh, M. J., Auletta, J. J., Lindemans, C. A., Zanis-Neto, J., Malvezzi, M., Lister, J., De Toledo Codina, J. S., Sackey, K., Chakrabarty, J. L H, Ljungman, P., Wingard, J. R., Seftel, M. D., Seo, S., Hale, G. A., Wirk, B., Smith, M S, Savani, B. N., Lazarus, H. M., Marks, D. I., Ustun, C., Abdel-Azim, H., Dvorak, C. C., Szer, J., Storek, J., Yong, A., Riches, M. R., UMC Utrecht, SCT patientenzorg, Child Health, Williams, K. M., Ahn, K. W., Chen, M., Aljurf, M. D., Agwu, A. L., Chen, A. R., Walsh, T. J., Szabolcs, P., Boeckh, M. J., Auletta, J. J., Lindemans, C. A., Zanis-Neto, J., Malvezzi, M., Lister, J., De Toledo Codina, J. S., Sackey, K., Chakrabarty, J. L H, Ljungman, P., Wingard, J. R., Seftel, M. D., Seo, S., Hale, G. A., Wirk, B., Smith, M S, Savani, B. N., Lazarus, H. M., Marks, D. I., Ustun, C., Abdel-Azim, H., Dvorak, C. C., Szer, J., Storek, J., Yong, A., and Riches, M. R.

Published
2016

124. Rabbit ATG for aplastic anaemia treatment: a backward step?

Author

European Blood, Marrow Transplant Group, Severe Aplastic Anaemia Working P.a.r.t.y. Dufour C, Bacigalupo A, Oneto R, Socie G, Tichelli A, Passweg JR, Schrezenmeier H, Locasciulli A, Aljurf M, Marsh J.C., RISITANO, ANTONIO MARIA, European, Blood, Marrow Transplant, Group, Dufour C, Severe Aplastic Anaemia Working P. a. r. t. y., Bacigalupo, A, Oneto, R, Socie, G, Tichelli, A, Passweg, Jr, Risitano, ANTONIO MARIA, Schrezenmeier, H, Locasciulli, A, Aljurf, M, and Marsh, J. C.

Subjects
business.industry, Anemia, Aplastic, General Medicine, Prognosis, Molecular biology, Risk Assessment, Sensitivity and Specificity, Severity of Illness Index, Survival Analysis, Treatment Outcome, Cyclosporine, Medicine, Animals, Humans, Rabbits, Rabbit ATG, business, Immunosuppressive Agents, Antilymphocyte Serum, Randomized Controlled Trials as Topic
Published
2011

125. Outcome of Allogeneic Stem Cell Transplantation for Patients Transformed to Myelodysplastic Syndrome or Leukemia from Severe Aplastic Anemia: A Report from the MDS Subcommittee of the Chronic Malignancies Working Party and the Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation

Author

Hussein, Aa, Halkes, Cm, Socié, G, Tichelli, A, Borne, Pa, Schaap, Mn, Foa, Roberto, Ganser, A, Dufour, C, Bacigalupo, A, Locasciulli, A, Aljurf, M, Peters, C, Robin, M, van Biezen AA, Volin, L, De Witte, T, Marsh, J, Passweg, Jr, Kröger, N, for the Severe Aplastic Anemia, Chronic Malignancies Working Parties of the European Group for Blood, and Marrow, Transplantation

Subjects
Adult, Male, medicine.medical_specialty, Transplantation Conditioning, Severe aplastic anemia, Adolescent, medicine.medical_treatment, Cancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2], Acute myelogenous leukemia, Hematopoietic stem cell transplantation, Myelogenous, Young Adult, Internal medicine, hemic and lymphatic diseases, medicine, Humans, Transplantation, Homologous, Child, Aged, Transplantation, Leukemia, Marrow transplantation, business.industry, Anemia, Aplastic, Infant, Hematology, Middle Aged, medicine.disease, Severe Aplastic Anemia, Europe, Treatment Outcome, surgical procedures, operative, Allogeneic hsct, Child, Preschool, Myelodysplastic Syndromes, Immunology, Female, Stem cell, Neoplasm Recurrence, Local, business, Myelodysplastic syndrome
Abstract

Item does not contain fulltext One hundred and forty patients who had undergone hematopoietic stem cell transplantation (HSCT) for myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML) transformation after treatment of severe aplastic anemia (SAA) were identified in the European Group for Blood and Marrow Transplantation (EBMT) database. The median age at HSCT was 29 years (range, 1 to 66 years). The transplant donor was related in 49% cases and unrelated in 51% cases. The 5-year probability of relapse was 17%, and that of nonrelapse mortality was 41%. The 5-year overall survival was 45% +/- 9%, better for patients untreated and patients in remission compared with patients with refractory disease. Our data indicate that allogeneic HSCT leads to prolonged survival in close to one-half of the patients transforming to MDS or AML from SAA.

Published
2014
Full Text
View/download PDF

126. HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN SEVERE CONGENITAL NEUTROPENIA: DATA FROM THE EUROPEAN GROUP FOR BLOOD AND MARROW TRANSPLANTATION

Author

Fioredda, F., Wreede, L. C., Biezen, A., T Veer-Tazelaar, N., Michaela Calvillo, Gaspar, B., Aljurf, M., Peters, C., Yesilipek, A., Fisher, A., Bierings, M., Donadieu, J., Ozturk, G., Ljungman, P., Or, R., Ganser, A., Veys, P., Matthes-Martin, S., Kalwak, K., Wynn, R., Afanasyev, B., Toledo Codina, J. S., Marsh, J., and Dufour, C.

Published
2014

127. Erratum: Impact of HLA mismatch direction on outcomes after umbilical cord blood transplantation for hematological malignant disorders: A retrospective Eurocord-EBMT analysis (Bone Marrow Transplantation (2014) 49 (864))

Author

Cunha, R., Loiseau, P., Ruggeri, A., Sanz, G., Michel, G., Iori, A. P., Socie, G., Arcese, W., Picardi, A., Dias De Heredia, C., Rio, B., Locatelli, F., O'Brien, T. A., Yakoub-Agha, I., Diaz, M. A., Milpied, N., Bittencourt, H., Souza, M. P., Aljurf, M., Charron, D., Boudjedir, K., Labopin, M., Gluckman, E., and Rocha, V.

Published
2014

128. Pre-existing invasive fungal infection is not a contraindication for allogeneic HSCT for patients with hematologic malignancies: a CIBMTR study

Author

Maziarz, R T, primary, Brazauskas, R, additional, Chen, M, additional, McLeod, A A, additional, Martino, R, additional, Wingard, J R, additional, Aljurf, M, additional, Battiwalla, M, additional, Dvorak, C C, additional, Geroge, B, additional, Guinan, E C, additional, Hale, G A, additional, Lazarus, H M, additional, Lee, J-W, additional, Liesveld, J L, additional, Ramanathan, M, additional, Reddy, V, additional, Savani, B N, additional, Smith, F O, additional, Strasfeld, L, additional, Taplitz, R A, additional, Ustun, C, additional, Boeckh, M J, additional, Gea-Banacloche, J, additional, Lindemans, C A, additional, Auletta, J J, additional, and Riches, M L, additional

Published
2016
Full Text
View/download PDF

129. GvHD after umbilical cord blood transplantation for acute leukemia: an analysis of risk factors and effect on outcomes

Author

Chen, Y-B, primary, Wang, T, additional, Hemmer, M T, additional, Brady, C, additional, Couriel, D R, additional, Alousi, A, additional, Pidala, J, additional, Urbano-Ispizua, A, additional, Choi, S W, additional, Nishihori, T, additional, Teshima, T, additional, Inamoto, Y, additional, Wirk, B, additional, Marks, D I, additional, Abdel-Azim, H, additional, Lehmann, L, additional, Yu, L, additional, Bitan, M, additional, Cairo, M S, additional, Qayed, M, additional, Salit, R, additional, Gale, R P, additional, Martino, R, additional, Jaglowski, S, additional, Bajel, A, additional, Savani, B, additional, Frangoul, H, additional, Lewis, I D, additional, Storek, J, additional, Askar, M, additional, Kharfan-Dabaja, M A, additional, Aljurf, M, additional, Ringden, O, additional, Reshef, R, additional, Olsson, R F, additional, Hashmi, S, additional, Seo, S, additional, Spitzer, T R, additional, MacMillan, M L, additional, Lazaryan, A, additional, Spellman, S R, additional, Arora, M, additional, and Cutler, C S, additional

Published
2016
Full Text
View/download PDF

130. Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation

Author

Mohty, M, primary, Malard, F, additional, Abecassis, M, additional, Aerts, E, additional, Alaskar, A S, additional, Aljurf, M, additional, Arat, M, additional, Bader, P, additional, Baron, F, additional, Bazarbachi, A, additional, Blaise, D, additional, Ciceri, F, additional, Corbacioglu, S, additional, Dalle, J-H, additional, Dignan, F, additional, Fukuda, T, additional, Huynh, A, additional, Masszi, T, additional, Michallet, M, additional, Nagler, A, additional, NiChonghaile, M, additional, Okamoto, S, additional, Pagliuca, A, additional, Peters, C, additional, Petersen, F B, additional, Richardson, P G, additional, Ruutu, T, additional, Savani, B N, additional, Wallhult, E, additional, Yakoub-Agha, I, additional, Duarte, R F, additional, and Carreras, E, additional

Published
2016
Full Text
View/download PDF

131. Paediatric reduced intensity conditioning : analysis of centre strategies on regimens and definitions by the EBMT Paediatric Diseases and Complications and Quality of Life WP

Author

Lawitschka, A., Faraci, M., Yaniv, I., Veys, P., Bader, P., Wachowiak, J., Socie, G., Aljurf, M. D., Arat, M., Boelens, J. J., Duarte, R., Tichelli, A., Peters, C., Lawitschka, A., Faraci, M., Yaniv, I., Veys, P., Bader, P., Wachowiak, J., Socie, G., Aljurf, M. D., Arat, M., Boelens, J. J., Duarte, R., Tichelli, A., and Peters, C.

Published
2015

132. Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with philadelphia chromosome positive acute lymphoblastic leukemia

Author

Brissot, E. (Eolia), Labopin, M. (Myriam), Beckers, M.M. (Marielle M.), Socié, G. (Gerard), Rambaldi, A. (Alessandro), Volin, L. (Liisa), Finke, J. (Jürgen), Lenhoff, S. (S.), Kröger, N. (Nicolaus), Ossenkoppele, G.J. (Gert), Craddock, C.F. (Charles), Yakoub-Agha, I. (Ibrahim), Gürman, G. (Günhan), Russell, N.H. (Nigel H.), Aljurf, M. (Mahmoud), Potter, M. (M.), Nagler, A. (Arnon), Ottmann, O.G., Cornelissen, J.J. (Jan), Esteve, J. (Jordi), Mohty, M. (Mohamad), Brissot, E. (Eolia), Labopin, M. (Myriam), Beckers, M.M. (Marielle M.), Socié, G. (Gerard), Rambaldi, A. (Alessandro), Volin, L. (Liisa), Finke, J. (Jürgen), Lenhoff, S. (S.), Kröger, N. (Nicolaus), Ossenkoppele, G.J. (Gert), Craddock, C.F. (Charles), Yakoub-Agha, I. (Ibrahim), Gürman, G. (Günhan), Russell, N.H. (Nigel H.), Aljurf, M. (Mahmoud), Potter, M. (M.), Nagler, A. (Arnon), Ottmann, O.G., Cornelissen, J.J. (Jan), Esteve, J. (Jordi), and Mohty, M. (Mohamad)

Abstract

This study aimed to determine the impact of tyrosine kinase inhibitors given pre- and post-allogeneic stem cell transplantation on long-term outcome of patients allografted for Philadelphia chromosome-positive acute lymphoblastic leukemia. This retrospective analysis from the EBMT Acute Leukemia Working Party included 473 de novoPhiladelphia chromosome-positive acute lymphoblastic leukemia patients in first complete remission who underwent an allogeneic stem cell transplantation using a human leukocyte antigen-identical sibling or human leukocyte antigen-matched unrelated donor between 2000 and 2010. Three hundred and ninety patients received tyrosine kinase inhibitors before transplant, 329 at induction and 274 at consolidation. Kaplan-Meier estimates of leukemia-free survival, overall survival, cumulative incidences of relapse incidence, and non-relapse mortality at five years were 38%, 46%, 36% and 26%, respectively. In multivariate analysis, tyrosine-kinase inhibitors given before allogeneic stem cell transplantation was associated with a better overall survival (HR=0.68; P=0.04) and was associated with lower relapse incidence (HR=0.5;P=0.01). In the post-transplant period, multivariate analysis identified prophylactic tyrosine-kinase inhibitor administration to be a significant factor for improved leukemia-free survival (HR=0.44; P=0.002) and overall survival (HR=0.42; P=0.004), and a lower relapse incidence (HR=0.40; P=0.01). Over the past decade, administration of tyrosine kinase inhibitors before allogeneic stem cell transplantation has significantly improved the long-term allogeneic stem cell transp

Published
2015
Full Text
View/download PDF

133. Paediatric reduced intensity conditioning: analysis of centre strategies on regimens and definitions by the EBMT Paediatric Diseases and Complications and Quality of Life WP

Author

Child Health, Infection & Immunity, SCT onderzoek, Lawitschka, A., Faraci, M., Yaniv, I., Veys, P., Bader, P., Wachowiak, J., Socie, G., Aljurf, M. D., Arat, M., Boelens, J. J., Duarte, R., Tichelli, A., Peters, C., Child Health, Infection & Immunity, SCT onderzoek, Lawitschka, A., Faraci, M., Yaniv, I., Veys, P., Bader, P., Wachowiak, J., Socie, G., Aljurf, M. D., Arat, M., Boelens, J. J., Duarte, R., Tichelli, A., and Peters, C.

Published
2015

134. Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia

Author

Brissot, E, Labopin, M, Beckers, MM, Socie, G, Rambaldi, A, Volin, L, Finke, J, Lenhoff, S, Kroger, N, Ossenkoppele, GJ, Craddock, CF, Yakoub-Agha, I, Gurman, G, Russell, NH, Aljurf, M, Potter, MN, Nagler, A, Ottmann, O, Cornelissen, Jan, Esteve, J, Mohty, M, Brissot, E, Labopin, M, Beckers, MM, Socie, G, Rambaldi, A, Volin, L, Finke, J, Lenhoff, S, Kroger, N, Ossenkoppele, GJ, Craddock, CF, Yakoub-Agha, I, Gurman, G, Russell, NH, Aljurf, M, Potter, MN, Nagler, A, Ottmann, O, Cornelissen, Jan, Esteve, J, and Mohty, M

Abstract

This study aimed to determine the impact of tyrosine kinase inhibitors given pre- and post- allogeneic stem cell transplantation on long- term outcome of patients allografted for Philadelphia chromosome- positive acute lymphoblastic leukemia. This retrospective analysis from the EBMT Acute Leukemia Working Party included 473 de novo Philadelphia chromosome- positive acute lymphoblastic leukemia patients in first complete remission who underwent an allogeneic stem cell transplantation using a human leukocyte antigen- identical sibling or human leukocyte antigen- matched unrelated donor between 2000 and 2010. Three hundred and ninety patients received tyrosine kinase inhibitors before transplant, 329 at induction and 274 at consolidation. Kaplan- Meier estimates of leukemia- free survival, overall survival, cumulative incidences of relapse incidence, and non- relapse mortality at five years were 38%, 46%, 36% and 26%, respectively. In multivariate analysis, tyrosine- kinase inhibitors given before allogeneic stem cell transplantation was associated with a better overall survival ( HR= 0.68; P= 0.04) and was associated with lower relapse incidence ( HR= 0.5; P= 0.01). In the post- transplant period, multivariate analysis identified prophylactic tyrosine- kinase inhibitor administration to be a significant factor for improved leukemiafree survival ( HR= 0.44; P= 0.002) and overall survival ( HR= 0.42; P= 0.004), and a lower relapse incidence ( HR= 0.40; P= 0.01). Over the past decade, administration of tyrosine kinase inhibitors before allogeneic stem cell transplantation has significantly improved the long- term allogeneic stem cell transplantation outcome of adult Philadelphia chromosome- positive acute lymphoblastic leukemia. Prospective studies will be of great interest to further confirm the potential benefit of the prophylactic use of tyrosine kinase inhibitors in the post- transplant setting.

Published
2015

135. Outcome of Allogeneic Stem Cell Transplantation for Patients Transformed to Myelodysplastic Syndrome or Leukemia from Severe Aplastic Anemia: A Report from the MDS Subcommittee of the Chronic Malignancies Working Party and the Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation

Author

Hussein, A.A., Halkes, C.M., Socie, G., Tichelli, A., Borne, P.A. von dem, Schaap, M.N., Foa, R., Ganser, A., Dufour, C., Bacigalupo, A., Locasciulli, A., Aljurf, M., Peters, C., Robin, M., Biezen, A.A. van, Volin, L., Witte, T.J. de, Marsh, J., Passweg, J.R., Kroger, N., et al., Hussein, A.A., Halkes, C.M., Socie, G., Tichelli, A., Borne, P.A. von dem, Schaap, M.N., Foa, R., Ganser, A., Dufour, C., Bacigalupo, A., Locasciulli, A., Aljurf, M., Peters, C., Robin, M., Biezen, A.A. van, Volin, L., Witte, T.J. de, Marsh, J., Passweg, J.R., Kroger, N., and et al.

Abstract

Item does not contain fulltext, One hundred and forty patients who had undergone hematopoietic stem cell transplantation (HSCT) for myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML) transformation after treatment of severe aplastic anemia (SAA) were identified in the European Group for Blood and Marrow Transplantation (EBMT) database. The median age at HSCT was 29 years (range, 1 to 66 years). The transplant donor was related in 49% cases and unrelated in 51% cases. The 5-year probability of relapse was 17%, and that of nonrelapse mortality was 41%. The 5-year overall survival was 45% +/- 9%, better for patients untreated and patients in remission compared with patients with refractory disease. Our data indicate that allogeneic HSCT leads to prolonged survival in close to one-half of the patients transforming to MDS or AML from SAA.

Published
2014

136. Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation

Author

Mohty, M., Huebel, K., Kroeger, N., Aljurf, M., Apperley, J., Basak, G. W., Bazarbachi, A., Douglas, K., Gabriel, I., Garderet, L., Geraldes, C., Jaksic, O., Kattan, M. W., Koristek, Z., Lanza, F., Lemoli, R. M., Mendeleeva, L., Mikala, G., Mikhailova, N., Nagler, A., Schouten, H. C., Selleslag, D., Suciu, S., Sureda, A., Worel, N., Wuchter, P., Chabannon, C., Duarte, R. F., Mohty, M., Huebel, K., Kroeger, N., Aljurf, M., Apperley, J., Basak, G. W., Bazarbachi, A., Douglas, K., Gabriel, I., Garderet, L., Geraldes, C., Jaksic, O., Kattan, M. W., Koristek, Z., Lanza, F., Lemoli, R. M., Mendeleeva, L., Mikala, G., Mikhailova, N., Nagler, A., Schouten, H. C., Selleslag, D., Suciu, S., Sureda, A., Worel, N., Wuchter, P., Chabannon, C., and Duarte, R. F.

Abstract

Autologous haematopoietic SCT with PBSCs is regularly used to restore BM function in patients with multiple myeloma or lymphoma after myeloablative chemotherapy. Twenty-eight experts from the European Group for Blood and Marrow Transplantation developed a position statement on the best approaches to mobilising PBSCs and on possibilities of optimising graft yields in patients who mobilise poorly. Choosing the appropriate mobilisation regimen, based on patients' disease stage and condition, and optimising the apheresis protocol can improve mobilisation outcomes. Several factors may influence mobilisation outcomes, including older age, a more advanced disease stage, the type of prior chemotherapy (e.g., fludarabine or melphalan), prior irradiation or a higher number of prior treatment lines. The most robust predictive factor for poor PBSC collection is the CD34(+) cell count in PB before apheresis. Determination of the CD34(+) cell count in PB before apheresis helps to identify patients at risk of poor PBSC collection and allows pre-emptive intervention to rescue mobilisation in these patients. Such a proactive approach might help to overcome deficiencies in stem cell mobilisation and offers a rationale for the use of novel mobilisation agents.

Published
2014

137. Autologous hematopoietic cell transplantation (autoHCT) for T‐cell/histiocyte‐rich large B‐cell lymphoma (THRLBCL): An EBMT Lymphoma Working Party study.

Author

Renders, S., Finel, H., Ngoya, M., Boumendil, A., Schaap, N., Ghesquieres, H., Bloor, A., Pérez‐Simón, J. A., Huynh, A., Kobbe, G., Collin, M., Busca, A., Helbig, G., Aljurf, M., Daskalakis, M., Schroers, R., Carpenter, B., Rubio, M. T., Peniket, A., and Sureda, A.

Subjects
HEMATOPOIETIC stem cell transplantation, LYMPHOMAS, DELAYED diagnosis, SEZARY syndrome
Abstract

THRLBCL patients were younger (52 vs. 58 years), predominantly male (76% vs. 59%), had better performance status (ECOG 0: 97% vs. 92%) and less comorbidity (HCT-CI 0: 78% vs. 68%), and had a longer time from diagnosis to transplant (13 vs. 11 months) than DLBCL patients. B Introduction: b THRLBCL is an orphan entity of large B-cell lymphomas (LBCL). Superior outcome of autoHCT for THRLBCL compared to DLBCL may be partly explained by more favorable baseline features of the THRLBCL group in terms of age, and PS. [Extracted from the article]

Published
2023
Full Text
View/download PDF

138. Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia

Author

Brissot, E., primary, Labopin, M., additional, Beckers, M. M., additional, Socie, G., additional, Rambaldi, A., additional, Volin, L., additional, Finke, J., additional, Lenhoff, S., additional, Kroger, N., additional, Ossenkoppele, G. J., additional, Craddock, C. F., additional, Yakoub-Agha, I., additional, Gurman, G., additional, Russell, N. H., additional, Aljurf, M., additional, Potter, M. N., additional, Nagler, A., additional, Ottmann, O., additional, Cornelissen, J. J., additional, Esteve, J., additional, and Mohty, M., additional

Published
2014
Full Text
View/download PDF

139. Alternative donors extend transplantation for patients with lymphoma who lack an HLA matched donor

Author

Bachanova, V, primary, Burns, L J, additional, Wang, T, additional, Carreras, J, additional, Gale, R P, additional, Wiernik, P H, additional, Ballen, K K, additional, Wirk, B, additional, Munker, R, additional, Rizzieri, D A, additional, Chen, Y-B, additional, Gibson, J, additional, Akpek, G, additional, Costa, L J, additional, Kamble, R T, additional, Aljurf, M D, additional, Hsu, J W, additional, Cairo, M S, additional, Schouten, H C, additional, Bacher, U, additional, Savani, B N, additional, Wingard, J R, additional, Lazarus, H M, additional, Laport, G G, additional, Montoto, S, additional, Maloney, D G, additional, Smith, S M, additional, Brunstein, C, additional, and Saber, W, additional

Published
2014
Full Text
View/download PDF

140. Outcome of aplastic anemia in adolescence: a survey of the Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation

Author

Dufour, C., primary, Pillon, M., additional, Passweg, J., additional, Socie, G., additional, Bacigalupo, A., additional, Franceschetto, G., additional, Carraro, E., additional, Oneto, R., additional, Risitano, A. M., additional, de Latour, R. P., additional, Tichelli, A., additional, Rovo, A., additional, Peters, C., additional, Hoechsmann, B., additional, Samarasinghe, S., additional, Kulasekararaj, A. G., additional, Schrezenmeier, H., additional, Aljurf, M., additional, and Marsh, J., additional

Published
2014
Full Text
View/download PDF

142. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: From the perspective of a large group of CML experts

Author

Abboud, C, Berman, E, Cohen, A, Cortes, J, Deangelo, D, Deininger, M, Devine, S, Druker, B, Fathi, A, Jabbour, E, Jagasia, M, Kantarjian, H, Khoury, J, Laneuville, P, Larson, R, Lipton, J, Moore, J, Mughal, T, O'Brien, S, Pinilla-Ibarz, J, Quintas-Cardama, A, Radich, J, Reddy, V, Schiffer, C, Shah, N, Shami, P, Silver, R, Snyder, D, Stone, R, Talpaz, M, Tefferi, A, Van Etten, R, Wetzler, M, Abruzzese, E, Apperley, J, Breccia, M, Byrne, J, Cervantes, F, Chelysheva, E, Clark, R, De Lavallade, H, Dyagil, I, Gambacorti-Passerini, C, Goldman, J, Haznedaroglu, I, Hjorth-Hansen, H, Holyoake, T, Huntly, B, Le Coutre, P, Lomaia, E, Mahon, F, Marin-Costa, D, Martinelli, G, Mayer, J, Milojkovic, D, Olavarria, E, Porkka, K, Richter, J, Rousselot, P, Saglio, G, Saydam, G, Stentoft, J, Turkina, A, Vigneri, P, Zaritskey, A, Aguayo, A, Ayala, M, Bendit, I, Bengio, R, Best, C, Bullorsky, E, Cervera, E, Desouza, C, Fanilla, E, Gomez-Almaguer, D, Hamerschlak, N, Lopez, J, Magarinos, A, Meillon, L, Milone, J, Moiraghi, B, Pasquini, R, Pavlovsky, C, Ruiz-Arguelles, G, Spector, N, Arthur, C, Browett, P, Grigg, A, Jianda, H, Huang, X, Hughes, T, Jiang, Q, Jootar, S, Kim, D, Malhotra, H, Malhotra, P, Matsumura, I, Melo, J, Ohnishi, K, Ohno, R, Saikia, T, Schwarer, A, Takahashi, N, Tam, C, Tauchi, T, Usuki, K, Wang, J, Abdel-Rahman, F, Aljurf, M, Bazarba-Chi, A, Yehuda, D, Chaudhri, N, Durosinmi, M, Kamel, H, Louw, V, Matti, B, Nagler, A, Raanani, P, Salem, Z, Abboud, Camille, Berman, Ellin, Cohen, Adam, Cortes, Jorge, DeAngelo, Daniel, Deininger, Michael, Devine, Steven, Druker, Brian, Fathi, Amir, Jabbour, Elias, Jagasia, Madan, Kantarjian, Hagop, Khoury, Jean, Laneuville, Pierre, Larson, Richard, Lipton, Jeffrey, Moore, Joseph O., Mughal, Tariq, O'Brien, Susan, Pinilla-Ibarz, Javier, Quintas-Cardama, Alfonso, Radich, Jerald, Reddy, Vishnu, Schiffer, Charles, Shah, Neil, Shami, Paul, Silver, Richard T., Snyder, David, Stone, Richard, Talpaz, Moshe, Tefferi, Ayalew, Van Etten, Richard A., Wetzler, Meir, Abruzzese, Elisabetta, Apperley, Jane, Breccia, Massimo, Byrne, Jenny, Cervantes, Francisco, Chelysheva, Ekaterina, Clark, R. E., De Lavallade, Hugues, Dyagil, Iryna, Gambacorti-Passerini, Carlo, Goldman, John, Haznedaroglu, Ibrahim, Hjorth-Hansen, Henrik, Holyoake, Tessa, Huntly, Brian, Le Coutre, Philipp, Lomaia, Elza, Mahon, Francois-Xavier, Marin-Costa, David, Martinelli, Giovanni, Mayer, Jiri, Milojkovic, Dragana, Olavarria, Eduardo, Porkka, Kimmo, Richter, Johan, Rousselot, Philippe, Saglio, Giuseppe, Saydam, Guray, Stentoft, Jesper, Turkina, Anna, Vigneri, Paolo, Zaritskey, Andrey, Aguayo, Alvaro, Ayala, Manuel, Bendit, Israel, Bengio, Raquel Maria, Best, Carlos, Bullorsky, Eduardo, Cervera, Eduardo, Desouza, Carmino, Fanilla, Ernesto, Gomez-Almaguer, David, Hamerschlak, Nelson, Lopez, Jose, Magarinos, Alicia, Meillon, Luis, Milone, Jorge, Moiraghi, Beatriz, Pasquini, Ricardo, Pavlovsky, Carolina, Ruiz-Arguelles, Guillermo J., Spector, Nelson, Arthur, Christopher, Browett, Peter, Grigg, Andrew, Hu, Jianda, Huang, Xiao-jun, Hughes, Tim, Jiang, Qian, Jootar, Saengsuree, Kim, Dong-Wook, Malhotra, Hemant, Malhotra, Pankaj, Matsumura, Itaru, Melo, Junia, Ohnishi, Kazunori, Ohno, Ryuzo, Saikia, Tapan, Schwarer, Anthony P., Takahashi, Naoto, Tam, Constantine, Tauchi, Tetsuzo, Usuki, Kensuke, Wang, Jianxiang, Abdel-Rahman, Fawzi, Aljurf, Mahmoud Deeb Saeed, Bazarba-Chi, Ali, Yehuda, Dina Ben, Chaudhri, Naeem, Durosinmi, Muheez, Kamel, Hossam, Louw, Vernon, Matti, Bassam Francis, Nagler, Arnon, Raanani, Pia, Salem, Ziad, Abboud, C, Berman, E, Cohen, A, Cortes, J, Deangelo, D, Deininger, M, Devine, S, Druker, B, Fathi, A, Jabbour, E, Jagasia, M, Kantarjian, H, Khoury, J, Laneuville, P, Larson, R, Lipton, J, Moore, J, Mughal, T, O'Brien, S, Pinilla-Ibarz, J, Quintas-Cardama, A, Radich, J, Reddy, V, Schiffer, C, Shah, N, Shami, P, Silver, R, Snyder, D, Stone, R, Talpaz, M, Tefferi, A, Van Etten, R, Wetzler, M, Abruzzese, E, Apperley, J, Breccia, M, Byrne, J, Cervantes, F, Chelysheva, E, Clark, R, De Lavallade, H, Dyagil, I, Gambacorti-Passerini, C, Goldman, J, Haznedaroglu, I, Hjorth-Hansen, H, Holyoake, T, Huntly, B, Le Coutre, P, Lomaia, E, Mahon, F, Marin-Costa, D, Martinelli, G, Mayer, J, Milojkovic, D, Olavarria, E, Porkka, K, Richter, J, Rousselot, P, Saglio, G, Saydam, G, Stentoft, J, Turkina, A, Vigneri, P, Zaritskey, A, Aguayo, A, Ayala, M, Bendit, I, Bengio, R, Best, C, Bullorsky, E, Cervera, E, Desouza, C, Fanilla, E, Gomez-Almaguer, D, Hamerschlak, N, Lopez, J, Magarinos, A, Meillon, L, Milone, J, Moiraghi, B, Pasquini, R, Pavlovsky, C, Ruiz-Arguelles, G, Spector, N, Arthur, C, Browett, P, Grigg, A, Jianda, H, Huang, X, Hughes, T, Jiang, Q, Jootar, S, Kim, D, Malhotra, H, Malhotra, P, Matsumura, I, Melo, J, Ohnishi, K, Ohno, R, Saikia, T, Schwarer, A, Takahashi, N, Tam, C, Tauchi, T, Usuki, K, Wang, J, Abdel-Rahman, F, Aljurf, M, Bazarba-Chi, A, Yehuda, D, Chaudhri, N, Durosinmi, M, Kamel, H, Louw, V, Matti, B, Nagler, A, Raanani, P, Salem, Z, Abboud, Camille, Berman, Ellin, Cohen, Adam, Cortes, Jorge, DeAngelo, Daniel, Deininger, Michael, Devine, Steven, Druker, Brian, Fathi, Amir, Jabbour, Elias, Jagasia, Madan, Kantarjian, Hagop, Khoury, Jean, Laneuville, Pierre, Larson, Richard, Lipton, Jeffrey, Moore, Joseph O., Mughal, Tariq, O'Brien, Susan, Pinilla-Ibarz, Javier, Quintas-Cardama, Alfonso, Radich, Jerald, Reddy, Vishnu, Schiffer, Charles, Shah, Neil, Shami, Paul, Silver, Richard T., Snyder, David, Stone, Richard, Talpaz, Moshe, Tefferi, Ayalew, Van Etten, Richard A., Wetzler, Meir, Abruzzese, Elisabetta, Apperley, Jane, Breccia, Massimo, Byrne, Jenny, Cervantes, Francisco, Chelysheva, Ekaterina, Clark, R. E., De Lavallade, Hugues, Dyagil, Iryna, Gambacorti-Passerini, Carlo, Goldman, John, Haznedaroglu, Ibrahim, Hjorth-Hansen, Henrik, Holyoake, Tessa, Huntly, Brian, Le Coutre, Philipp, Lomaia, Elza, Mahon, Francois-Xavier, Marin-Costa, David, Martinelli, Giovanni, Mayer, Jiri, Milojkovic, Dragana, Olavarria, Eduardo, Porkka, Kimmo, Richter, Johan, Rousselot, Philippe, Saglio, Giuseppe, Saydam, Guray, Stentoft, Jesper, Turkina, Anna, Vigneri, Paolo, Zaritskey, Andrey, Aguayo, Alvaro, Ayala, Manuel, Bendit, Israel, Bengio, Raquel Maria, Best, Carlos, Bullorsky, Eduardo, Cervera, Eduardo, Desouza, Carmino, Fanilla, Ernesto, Gomez-Almaguer, David, Hamerschlak, Nelson, Lopez, Jose, Magarinos, Alicia, Meillon, Luis, Milone, Jorge, Moiraghi, Beatriz, Pasquini, Ricardo, Pavlovsky, Carolina, Ruiz-Arguelles, Guillermo J., Spector, Nelson, Arthur, Christopher, Browett, Peter, Grigg, Andrew, Hu, Jianda, Huang, Xiao-jun, Hughes, Tim, Jiang, Qian, Jootar, Saengsuree, Kim, Dong-Wook, Malhotra, Hemant, Malhotra, Pankaj, Matsumura, Itaru, Melo, Junia, Ohnishi, Kazunori, Ohno, Ryuzo, Saikia, Tapan, Schwarer, Anthony P., Takahashi, Naoto, Tam, Constantine, Tauchi, Tetsuzo, Usuki, Kensuke, Wang, Jianxiang, Abdel-Rahman, Fawzi, Aljurf, Mahmoud Deeb Saeed, Bazarba-Chi, Ali, Yehuda, Dina Ben, Chaudhri, Naeem, Durosinmi, Muheez, Kamel, Hossam, Louw, Vernon, Matti, Bassam Francis, Nagler, Arnon, Raanani, Pia, and Salem, Ziad

Abstract

As a group of more than 100 experts in chronic myeloid leukemia (CML), we draw attention to the high prices of cancer drugs, with the particular focus on the prices of approved tyrosine kinase inhibitors for the treatment of CML. This editorial addresses the multiple factors involved in cancer drug pricing and their impact on individual patients and health care policies, and argues for the need to (1) lower the prices of cancer drugs to allow more patients to afford them and (2) maintain sound long-term health care policies.

Published
2013

143. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation.

Author

Majhail, NS, Rizzo, JD, Lee, SJ, Aljurf, M, Atsuta, Y, Bonfim, C, Burns, LJ, Chaudhri, N, Davies, S, Okamoto, S, Seber, A, Socie, G, Szer, J, Lint, MTV, Wingard, JR, Tichelli, A, Majhail, NS, Rizzo, JD, Lee, SJ, Aljurf, M, Atsuta, Y, Bonfim, C, Burns, LJ, Chaudhri, N, Davies, S, Okamoto, S, Seber, A, Socie, G, Szer, J, Lint, MTV, Wingard, JR, and Tichelli, A

Abstract

Advances in hematopoietic cell transplantation (HCT) technology and supportive care techniques have led to improvements in long-term survival after HCT. Emerging indications for transplantation, introduction of newer graft sources (e.g. umbilical cord blood) and transplantation of older patients using less intense conditioning regimens have also contributed to an increase in the number of HCT survivors. These survivors are at risk for developing late complications secondary to pre-, periand post-transplant exposures and risk-factors. Guidelines for screening and preventive practices for HCT survivors were published in 2006. An international group of transplant experts was convened in 2011 to review contemporary literature and update the recommendations while considering the changing practice of transplantation and international applicability of these guidelines. This review provides the updated recommendations for screening and preventive practices for pediatric and adult survivors of autologous and allogeneic HCT.

Published
2012

144. Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual disease

Author

Bachanova, V, primary, Marks, D I, additional, Zhang, M-J, additional, Wang, H, additional, de Lima, M, additional, Aljurf, M D, additional, Arellano, M, additional, Artz, A S, additional, Bacher, U, additional, Cahn, J-Y, additional, Chen, Y-B, additional, Copelan, E A, additional, Drobyski, W R, additional, Gale, R P, additional, Greer, J P, additional, Gupta, V, additional, Hale, G A, additional, Kebriaei, P, additional, Lazarus, H M, additional, Lewis, I D, additional, Lewis, V A, additional, Liesveld, J L, additional, Litzow, M R, additional, Loren, A W, additional, Miller, A M, additional, Norkin, M, additional, Oran, B, additional, Pidala, J, additional, Rowe, J M, additional, Savani, B N, additional, Saber, W, additional, Vij, R, additional, Waller, E K, additional, Wiernik, P H, additional, and Weisdorf, D J, additional

Published
2013
Full Text
View/download PDF

145. Impact of HLA mismatch direction on outcomes after umbilical cord blood transplantation for hematological malignant disorders: a retrospective Eurocord-EBMT analysis

Author

Cunha, R, primary, Loiseau, P, additional, Ruggeri, A, additional, Sanz, G, additional, Michel, G, additional, PaolaIori, A, additional, Socié, G, additional, Arcese, W, additional, Picardi, A, additional, Dias de Heredia, C, additional, Rio, B, additional, Locatelli, F, additional, O'Brien, T A, additional, Yakoub-Agha, I, additional, Angel Diaz, M, additional, Milpied, N, additional, Bittencourt, H, additional, Pedro Souza, M, additional, Aljurf, M, additional, Charron, D, additional, Boudjedir, K, additional, Labopin, M, additional, Gluckman, E, additional, and Rocha, V, additional

Published
2013
Full Text
View/download PDF

147. Relationship between clinical and BK virological response in patients with late hemorrhagic cystitis treated with cidofovir: a retrospective study from the European Group for Blood and Marrow Transplantation

Author

Cesaro, S, primary, Pillon, M, additional, Tridello, G, additional, Aljurf, M, additional, Martino, R, additional, Schroyens, W, additional, Nozzoli, C, additional, Barba, P, additional, Faraci, M, additional, Fagioli, F, additional, Cappelli, B, additional, Cordonnier, C, additional, Al-Mohareb, F, additional, Floisand, Y, additional, Greil, J, additional, Panizzolo, I S, additional, and Santarone, S, additional

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results